Microbot Medical MBOT Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies
Other financials
Where this comes from
Reported directly by Microbot Medical in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Microbot Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Microbot Medical's total cash, cash equivalents, and restricted cash (inclusive).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Microbot Medical's total cash, cash equivalents, and restricted cash (inclusive)?
- Microbot Medical (MBOT) reported total cash, cash equivalents, and restricted cash (inclusive) of $3.92M in Q1 2026.
- How has Microbot Medical's total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
- Microbot Medical's total cash, cash equivalents, and restricted cash (inclusive) increased by 20.0% year-over-year, from $3.27M to $3.92M.
- What is the long-term trend for Microbot Medical's total cash, cash equivalents, and restricted cash (inclusive)?
- Over 5 years (2020 to 2025), Microbot Medical's total cash, cash equivalents, and restricted cash (inclusive) has grown at a -27.4% compound annual growth rate (CAGR), from $19.73M to $3.97M.
- What does total cash, cash equivalents, and restricted cash (inclusive) mean?
- The aggregate of all cash, highly liquid investments, and restricted cash balances held by the company, including amounts associated with discontinued operations. This metric serves as the primary indicator of the company's immediate financial health and ability to fund ongoing research and development. It is a critical measure for pre-clinical companies to determine their cash runway.